Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management

被引：23
作者：
Cooperberg M.R. [1 ]
Broering J.M. [1 ]
Latini D.M. [1 ]
Litwin M.S. [1 ]
Wallace K.L. [1 ]
Carroll P.R. [1 ]
机构：
[1] Mount Zion Cancer Center, University of California, San Francisco, 1600 Divisadero Street, 6th Floor, San Francisco, 94115-1711, CA
来源：
Current Urology Reports | 2004年 / 5卷 / 3期
关键词：
Gleason Score; Localize Prostate Cancer; Prostate Cancer; Prostate Cancer Management; Radical Prostatectomy;
D O I：
10.1007/s11934-004-0033-7
中图分类号：
学科分类号：
摘要：
The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national disease registry of more than 10,000 patients with prostate cancer treated at 31 primarily community-based sites across the country. The database tracks oncologic and health-related quality-of-life outcomes. Because the urologists participating in the project treat according to their usual practices, CaPSURE facilitates the study of trends in disease-management strategies, offering a reflection of “real world” practice patterns. This review highlights key studies during the past several years that document downward risk migration, validates widely used prognostic nomograms, establishes prostatespecific antigen doubling time as a surrogate endpoint for disease-specific mortality, assesses the impact of treatment on patient-reported quality of life, and presents national trends in imaging test use and primary treatment strategies for localized disease. © 2004, Current Science Inc.
引用
收藏
页码：166 / 172
页数：6
相关论文
共 41 条
  • [1] Holmberg L., Bill-Axelson A., Helgesen F., Et al., A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer, N Engl J Med, 347, pp. 781-789, (2002)
  • [2] Lubeck D.P., Litwin M.S., Henning J.M., Et al., The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor, Urology, 48, pp. 773-777, (1996)
  • [3] Cooperberg M.R., Lubeck D.P., Penson D.F., Et al., Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE, J Urol, 170, pp. 905-908, (2003)
  • [4] D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, pp. 969-974, (1998)
  • [5] Cooperberg M.R., Lubeck D.P., Mehta S.S., Carroll P.R., Time trends in clinical risk stratification for prostate cancer: implications for outcomes (Data from CaPSURE), J Urol, 170, pp. S21-S27, (2003)
  • [6] Smith E.B., Frierson H.F., Mills S.E., Et al., Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading?, Cancer, 94, pp. 2282-2287, (2002)
  • [7] Presti J.C., Shinohara K., Bacchetti P., Et al., Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy, Urology, 52, pp. 1079-1084, (1998)
  • [8] D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer, J Clin Oncol, 18, pp. 1164-1172, (2000)
  • [9] Freedland S.J., Csathy G.S., Dorey F., Aronson W.J., Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate-specific antigen or Gleason score, J Urol, 167, pp. 516-520, (2002)
  • [10] Grossfeld G.D., Latini D.M., Lubeck D.P., Et al., Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE, Urology, 59, pp. 560-565, (2002)
12345